Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PFE Stock Forecast 2026-2027
$26.00
Current Price
$148.19B
Market Cap
Buy 11
Hold 16
Sell 2
Wall St Analyst Ratings
Distance to PFE Price Targets
+38.5%
To High Target of $36.00
+7.7%
To Median Target of $28.00
-7.7%
To Low Target of $24.00
PFE Price Momentum
+1.2%
1 Week Change
+2.6%
1 Month Change
+6.6%
1 Year Change
+4.4%
Year-to-Date Change
-9.6%
From 52W High of $28.75
+12.5%
From 52W Low of $23.11
📊 TOP ANALYST CALLS
Did PFE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Pfizer is one of their latest high-conviction picks.
Latest PFE Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, PFE has a neutral consensus with a median price target of $28.00 (ranging from $24.00 to $36.00). The overall analyst rating is Buy (7.2/10). Currently trading at $26.00, the median forecast implies a 7.7% upside. This outlook is supported by 11 Buy, 16 Hold, and 2 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PFE Analyst Ratings
11
Buy
16
Hold
2
Sell
PFE Price Target Range
Low
$24.00
Average
$28.00
High
$36.00
Current: $26.00
Latest PFE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PFE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 10, 2026 | RBC Capital | Trung Huynh | Sector Perform | Upgrade | $25.00 |
| Apr 29, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Apr 20, 2026 | RBC Capital | Underperform | Reiterates | $N/A | |
| Apr 16, 2026 | CICC | Outperform | Initiates | $N/A | |
| Apr 13, 2026 | UBS | Neutral | Maintains | $N/A | |
| Apr 10, 2026 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Apr 9, 2026 | B of A Securities | Neutral | Maintains | $N/A | |
| Mar 24, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Mar 17, 2026 | HSBC | Buy | Maintains | $N/A | |
| Mar 2, 2026 | Argus Research | Buy | Upgrade | $N/A | |
| Feb 25, 2026 | RBC Capital | Underperform | Initiates | $N/A | |
| Feb 20, 2026 | Barclays | Underweight | Initiates | $N/A | |
| Feb 9, 2026 | Freedom Broker | Buy | Maintains | $N/A | |
| Feb 4, 2026 | Cantor Fitzgerald | Neutral | Reiterates | $N/A | |
| Jan 27, 2026 | Cantor Fitzgerald | Neutral | Maintains | $N/A | |
| Jan 7, 2026 | UBS | Michael Yee | Neutral | Assumes | $25.00 |
| Dec 17, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Dec 15, 2025 | B of A Securities | Neutral | Maintains | $N/A | |
| Dec 12, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Dec 2, 2025 | Citigroup | Geoff Meacham | Neutral | Reinstates | $26.00 |
Pfizer Inc. (PFE) Competitors
The following stocks are similar to Pfizer based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pfizer Inc. (PFE) Financial Data
Pfizer Inc. has a market capitalization of $148.19B with a P/E ratio of 19.8x. The company generates $63.32B in trailing twelve-month revenue with a 11.8% profit margin.
Revenue growth is +5.4% quarter-over-quarter, while maintaining an operating margin of +31.6% and return on equity of +8.3%.
Valuation Metrics
Market Cap
$148.19B
Enterprise Value
$200.14B
P/E Ratio
19.8x
PEG Ratio
-2.1x
Price/Sales
2.3x
Growth & Margins
Revenue Growth (YoY)
+5.4%
Gross Margin
+75.4%
Operating Margin
+31.6%
Net Margin
+11.8%
EPS Growth
-9.4%
Financial Health
Cash/Price Ratio
+8.8%
Current Ratio
1.2x
Debt/Equity
71.6x
ROE
+8.3%
ROA
+5.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Pfizer Inc. (PFE) Business Model
About Pfizer Inc.
What They Do
Develops and sells prescription drugs and vaccines.
Business Model
Pfizer Inc. operates as a biopharmaceutical company, generating revenue through the discovery, development, manufacturing, marketing, and distribution of a diverse range of prescription drugs and vaccines. The company focuses on several therapeutic areas, including oncology, cardiology, immunology, and infectious diseases, ensuring a steady income stream from both established products and new innovations.
Additional Information
Founded in 1849 and headquartered in New York, Pfizer has a significant international presence, with a notable share of sales coming from emerging markets. Its key products include vaccines like Prevnar 13 and treatments such as Vyndaqel, Eliquis, and Padcev, which address critical health needs and contribute to global healthcare delivery.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
75,000
CEO
Dr. Albert Bourla D.V.M., Ph.D.
Country
United States
IPO Year
1972
Website
www.pfizer.comPfizer Inc. (PFE) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Top Research Reports for Pfizer, Altria & Newmont Corp.
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Altria Group, Inc. (MO) and Newmont Corp. (NEM), as well as two micro-cap stocks, Koil Energy Solutions, Inc. (KLNG) and Stratus Properties Inc. (STRS).
Jun 15, 2026
By Mark Vickery
Research Daily
Is Pfizer's Discounted Valuation a Buying Opportunity or a Value Trap?
PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline plans could shape its future.
Jun 15, 2026
By Kinjel Shah
Analyst Blog
Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines?
BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.
Jun 12, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Pfizer is undergoing a significant transformation by integrating the Seagen oncology platform and newly acquired Metsera obesity assets to counteract declining COVID revenues and upcoming patent expirations.
Why It Matters
Pfizer's strategic shift to oncology and obesity assets signals potential growth, crucial for offsetting declining COVID revenues and patent expirations, impacting future profitability and stock performance.
Source: 24/7 Wall Street
Market Sentiment:
Positive
A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25
4 days ago
Quick Summary
Pfizer (NYSE:PFE) is currently priced at $25.60, with Wall Street's consensus rating indicating a "Hold" status.
Why It Matters
Pfizer's $25.60 price indicates a neutral stance from analysts, suggesting limited growth potential and influencing investment decisions around the stock.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Why Pfizer Stock Popped Today
4 days ago
Quick Summary
RBC upgraded Pfizer, removing its sell rating. The stock is down 11% from its highs and offers a 6.7% dividend yield.
Why It Matters
RBC's upgrade signals potential confidence in Pfizer's recovery, suggesting a buying opportunity. The high dividend yield may attract income-focused investors amid recent stock declines.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Pfizer (PFE) shares closed at $26.14, reflecting a 2.11% increase from the previous trading session.
Why It Matters
Pfizer's recent price increase indicates positive market sentiment, potentially boosting investor confidence and suggesting improved performance or outlook for the company.
Source: Zacks Investment Research
Market Sentiment:
Positive
Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy
3 days ago
Quick Summary
Eli Lilly (NYSE: LLY) has surged 20.9% in one month, now valued at $1.02 trillion, driven by its strong position in the obesity market.
Why It Matters
Eli Lilly's rapid stock increase highlights strong market confidence in its obesity treatments, potentially driving further investment and influencing sector valuations.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Quick Summary
Pfizer is entering the weight loss drug market with berobenatide, which is meeting performance expectations.
Why It Matters
Pfizer's entry into the weight loss drug market with promising results from berobenatide could lead to significant revenue growth, impacting stock performance and market competitiveness.
Source: The Motley Fool
Market Sentiment:
Negative
Frequently Asked Questions About PFE Stock
What is Pfizer Inc.'s (PFE) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Pfizer Inc. (PFE) has a median price target of $28.00. The highest price target is $36.00 and the lowest is $24.00.
Is PFE stock a good investment in 2026?
According to current analyst ratings, PFE has 11 Buy ratings, 16 Hold ratings, and 2 Sell ratings. The stock is currently trading at $26.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PFE stock?
Wall Street analysts predict PFE stock could reach $28.00 in the next 12 months. This represents a 7.7% increase from the current price of $26.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pfizer Inc.'s business model?
Pfizer Inc. operates as a biopharmaceutical company, generating revenue through the discovery, development, manufacturing, marketing, and distribution of a diverse range of prescription drugs and vaccines. The company focuses on several therapeutic areas, including oncology, cardiology, immunology, and infectious diseases, ensuring a steady income stream from both established products and new innovations.
What is the highest forecasted price for PFE Pfizer Inc.?
Price targets from Wall Street analysts for PFE are not currently available. The stock is trading at $26.00.
What is the lowest forecasted price for PFE Pfizer Inc.?
The lowest price target for PFE is $24.00 from at , which represents a -7.7% decrease from the current price of $26.00.
What is the overall PFE consensus from analysts for Pfizer Inc.?
The overall analyst consensus for PFE is neutral. Out of 6 Wall Street analysts, 11 rate it as Buy, 16 as Hold, and 2 as Sell, with a median price target of $28.00.
How accurate are PFE stock price projections?
Stock price projections, including those for Pfizer Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 5:13 AM UTC